David L. Porter
Treated the first adult CLL patients with CAR-T and reported a decade of durable remissions.
Led the clinical side of Penn's first CTL019 studies in CLL and the 10-year follow-up showing persistent CAR-T cells in long-term responders.
| Title | Journal | Year |
|---|---|---|
| Decade-long leukaemia remissions with persistence of CD4+ CAR T cells | Nature | 2022 |
Pages like this
not linked directly; found by shared links- PersonCarl H. June
Shares Emily Whitehead, Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania.
- TrialELIANA
Shares Emily Whitehead, Tisagenlecleucel, CD19, Acute lymphoblastic leukaemia.
- PersonBruce L. Levine
Shares Emily Whitehead, Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, Abramson Cancer Center, University of Pennsylvania, CAR-T cell therapy.
- Key paperELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL
Shares Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania, CD19.
- PersonJae H. Park
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- TrialTRANSCEND CLL 004
Shares CD19, Chronic lymphocytic leukaemia, CAR-T cell therapy.
- Key paperJULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma
Shares Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania, CD19, CAR-T cell therapy.
- InstitutionChildren's Hospital of Philadelphia
Shares Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania, CD19, Acute lymphoblastic leukaemia.